Regulatory Developments On Pharmaceutical Intellectual Property Rights
This article was originally published in PharmAsia News
Executive Summary
China Intellectual Property News published an article introducing the laws and regulations on intellectual property rights for pharmaceuticals. Related laws cover patent, trademark, drug administration and anti-trust competition. Reviews are provided on regulatory provisions for new drugs approvals, protection of new medicines and technology transfer, administrative protection of pharmaceuticals, drug registration, and protection of TCM. The overview summarized the protection of pharmaceuticals from different aspects-protection terms, major content and newly revised items after China's entry to the World Trade Organization. Last year, the country ratified an amended version of WTO's Agreement of the Trade-Related Aspects of Intellectual Property Rights, which attempts to strike a balance between IPRs and public health. (Click here for more - Chinese Language)
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.